Future directions in the evaluation of c-MET-driven malignancies

Future directions in the evaluation of c-MET-driven malignancies

The c-MET (mesenchymal–epithelial transition factor) receptor tyrosine kinase is an exciting novel drug target in view of its key role in oncogenesis, as well as its association with disease prognosis in a number of malignancies. Several drugs targeting c-MET are currently showing promise in clinica...

Full description

Bibliographic Details
Main Authors:	Johann S. de Bono, Timothy A. Yap
Format:	Article
Language:	English
Published:	SAGE Publishing 2011-11-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758834011423540

Similar Items

c-MET: an exciting new target for anticancer therapy
by: Johann S. de Bono, et al.
Published: (2011-11-01)

MET targeted therapy for lung cancer: clinical development and future directions
by: Feng Y, et al.
Published: (2012-08-01)

Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy
by: Xin Liu, et al.
Published: (2020-01-01)

HGF/MET Signaling in Malignant Brain Tumors
by: Elizabeth Qian Xu Mulcahy, et al.
Published: (2020-10-01)

Treatment of malignant pleural mesothelioma: current status and future directions
by: X. Dhalluin, et al.
Published: (2016-01-01)

In Vivo Direct Molecular Imaging of Early Tumorigenesis and Malignant Progression Induced by Transgenic Expression of GFP-Met
by: Sharon Moshitch-Moshkovitz, et al.
Published: (2006-05-01)

Current available therapies and future directions in the treatment of malignant gliomas
by: Annick Desjardins, et al.
Published: (2008-12-01)

Development of c-Met targeted chimeric antigen receptor T-cell immunotherapy for malignant pleural mesothelioma
by: Thayaparan, Thivyan
Published: (2016)

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
by: Dearbhaile Catherine Collins, et al.
Published: (2020-12-01)

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
by: Thivyan Thayaparan, et al.
Published: (2017-12-01)

Cerebral Metastases from Malignant Melanoma: Current Treatment Strategies, Advances in Novel Therapeutics and Future Directions
by: Timothy L. Siu, et al.
Published: (2010-04-01)

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
by: Lluís Nisa, et al.
Published: (2017-05-01)

Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
by: Dearbhaile Catherine Collins, et al.
Published: (2021-03-01)

Correlation of MET and PD-L1 Expression in Malignant Melanoma
by: Kyu Young Song, et al.
Published: (2020-07-01)

c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells
by: Erica Leonetti, et al.
Published: (2019-01-01)

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis
by: Giovanni Gaudino, et al.
Published: (2014-11-01)

Current knowledge and future research directions in treatment-related second primary malignancies
by: Lindsay M. Morton, et al.
Published: (2014-06-01)

In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs
by: Neelesh Sharma, et al.
Published: (2011-11-01)

Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer
by: Ling Lim, et al.
Published: (2019-01-01)

A receptor-antibody hybrid hampering MET-driven metastatic spread
by: Chiara Modica, et al.
Published: (2021-01-01)

The Role of PI3K in Met Driven Cancer: A Recap
by: Alexia Hervieu, et al.
Published: (2018-10-01)

CAL evaluation: future directions
by: Cathy Gunn
Published: (1997-12-01)

c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.
by: Yingbo Li, et al.
Published: (2014-01-01)

Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody
by: Huang L, et al.
Published: (2020-08-01)

Teenswoordige geskiedenis: Michel Foucault in gesprek met die teologie
by: Johann Beukes
Published: (2004-12-01)

An overview of the c-MET signaling pathway
by: Shawna Leslie Organ, et al.
Published: (2011-11-01)

Expression of c-MET in Invasive Meningioma
by: Sumi Yun, et al.
Published: (2015-01-01)

c-Met and miRs in Cancer
by: Simona Giglio, et al.
Published: (2015-01-01)

Studies on the human c-Met receptor
by: Sirulnik, Leonardo Andres
Published: (1995)

Oncolytic adenovirus driven by hypoxia- inducible Met promoter for the treatment of hepatocellular carcinoma
by: Hao-Tien Wang, et al.
Published: (2005)

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer
by: Huilai Lv, et al.
Published: (2015-01-01)

Placental pseudo-malignancy from a DNA methylation perspective: unanswered questions and future directions
by: Boris eNovakovic, et al.
Published: (2013-12-01)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
by: Liang H, et al.
Published: (2020-03-01)

A theory-driven evaluation of a wellness initiative
by: Carren Field, et al.
Published: (2012-07-01)

Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma.
by: Irena Ivanovska, et al.
Published: (2011-01-01)

Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma
by: Birgit Lohberger, et al.
Published: (2021-06-01)

Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
by: Dilip Narayanan, et al.
Published: (2017-07-01)

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.
by: Sameer A Greenall, et al.
Published: (2012-01-01)

Hepatitis C in the Russian Federation: challenges and future directions
by: Mukomolov S, et al.
Published: (2016-05-01)

Anderbereddering: Met Adorno by die hartslag van die postmoderne intellek
by: Johann C. Beukes
Published: (1996-12-01)